Aktienanalyse zu MannKind Corp (MNKD)MNKDMannKind Corp

MannKind Corporation is a biopharmaceutical company engaged in transforming chronic disease care through patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, it develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. Its commercial assets include Afrezza, FUROSCIX and V-Go along with Tyvaso DPI. Its commercializing Afrezza (insulin human) Inhalation Powder, an ultra-rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin. Its orphan lung disease product, Tyvaso DPI (treprostinil) inhalation powder, is used in the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

MannKind Corp is not a strong buy at the current price of $3.95, despite recent FDA approval for Furoscix ReadyFlow, which could enhance revenue. The RSI is at 39.79, indicating the stock is nearing oversold territory, but the forward P/E ratio is extremely high at 119.05, suggesting overvaluation. Additionally, the stock has seen a significant decline of 29.46% year-to-date, which raises concerns about its current performance. The main risk is the net income loss of $19 million reported in Q2 2026, which could impact investor confidence.

2 analysts cover MNKD: 2 rate it Buy, 0 Hold and 0 Sell. The average price target is 9.25.